Table 3.
Age-adjusted and multivariable-adjusted annual mean changes in eGFR stratified by baseline urinary albumin excretion.
| Group | Subgroup | Number of patients (n = 1069) | Age-adjusted annual decline of eGFR | 95% CI | Multivariable-adjusted annual decline of eGFR | 95% CI | p value |
|---|---|---|---|---|---|---|---|
| Baseline UAE < 30 mg/g | |||||||
| Low | 170 | −0.72 | (−1.63, 0.19) | −0.33 | (−1.11, 0.43) | p = 0.109 | |
| Middle | 171 | −1.18* | (−2.11, −0.25) | −1.33* | (−2.14, −0.52) | ||
| High | 171 | −1.35* | (−2.40, −0.29) | −1.34* | (−2.20, −0.48) | ||
| 30 < Baseline UAE < 300 mg/g | |||||||
| Low | 126 | −0.76 | (−2.04, 0.52) | −0.75 | (−1.93, 0.42) | p = 0.019 | |
| Middle | 127 | −2.04*** | (−3.14, −0.94) | −2.36*** | (−3.46, −1.26) | ||
| High | 126 | −2.86*** | (−4.24, −1.49) | −2.76*** | (−3.96, −1.55) | ||
| Baseline UAE > 300 mg/g | |||||||
| Low | 59 | −2.46* | (−4.60, −0.31) | −2.43* | (−4.27, −0.59) | p = 0.219 | |
| Middle | 60 | −3.97*** | (−3.26, −0.70) | −3.56*** | (−5.35, −1.76) | ||
| High | 59 | −4.51*** | (−6.99, −2.03) | −4.20*** | (−6.48, −1.93) | ||
Adjusted for gender, the number of OADs, insulin usage, HTN medication, hyperlipidemia medication, age, baseline HbA1c (%), systolic blood pressure (mmHg).
CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HTN, hypertension; OAD, oral anti-diabetic drug; UAE, urinary albumin excretion.
*
p < 0.05 *** p < 0.001. compared with baseline renal function.